Search Results

Plus Therapeutics, Inc. today announced it has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).

PathMaker Neurosystems Inc. announced that it has received a funding award of $2.16 million from the Congressionally Directed Medical Research Program at the United States Department of Defense’s U.S. Army Medical Research and Development Command, as part of its FY23 Amyotrophic Lateral Sclerosis Research Program Pilot Clinical Trial Award.

Evotec SE announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., was selected by the U.S. Department of Defense to develop an accelerated monoclonal antibody development and manufacturing solution for the DOD’s Manufacturing Optimization Program.

Tonix Pharmaceuticals Holding Corp. announced it has been awarded an Other Transaction Agreement with a potential for up to $34 million over five years by the Defense Threat Reduction Agency, an agency within the U.S. Department of Defense.

Delix Therapeutics announced it has been awarded a $825,000 grant from the U.S. Department of Defense (DOD), to support the advancement of a neuroplastogen for hearing loss treatment.

RespireRx Pharmaceuticals Inc. is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study.

The BIOSECURE Act, which seeks to protect U.S. national security from Chinese biotech companies, will not be part of the House of Representatives vote on the 2025 fiscal year National Defense Authorization Act.

Telix Pharmaceuticals Limited (the “Company” or “Telix”) today announces the launch of its initial public offering in the United States (the “Offering”) of 17,000,000 American Depositary Shares (“ADSs”), each representing one ordinary share in Telix.